2024-09-07 - Analysis Report
## VRTX Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals, Inc. (VRTX) is a global biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious and life-threatening diseases.

**Performance Analysis:**

**1. Performance vs. S&P 500:**

* **Cumulative Return:** VRTX: 141.66%, VOO (S&P 500): 89.66%
* **Outperformance:** VRTX has significantly outperformed the S&P 500, with a 52.0% difference in cumulative returns. This represents a 91.44% percentile compared to historical outperformance data.

**2. Recent Price Movement:**

* **Closing Price:** $495.89
* **5-Day Moving Average:** $488.38
* **20-Day Moving Average:** $478.45
* **60-Day Moving Average:** $482.04

The stock is trading above its 5, 20, and 60-day moving averages, indicating short-term upward momentum. 

**3. Technical Indicators:**

* **RSI:** 79.95 - The RSI is in overbought territory, suggesting the stock may be due for a correction.
* **PPO:** 0.39 - The PPO indicates positive momentum, but the RSI suggests caution.
* **Delta_Previous_Relative_Divergence:** -6.98 - Recent relative divergence has been negative, indicating potential short-term downward pressure.
* **Expected Return:** 5.46% - This represents a potential 5-year expected return on investment, but it's important to remember that this is just an estimate.

**4. Recent Earnings and Outlook:**

| Date       | EPS       | Revenue     |
|-------------|-----------|-------------|
| 2024-08-02 | -13.92     | 2.65 B$      |
| 2024-05-07 | 4.26       | 2.69 B$      |
| 2023-11-07 | 4.01       | 2.48 B$      |
| 2023-08-02 | 3.55       | 2.49 B$      |
| 2024-08-02 | 3.55       | 2.49 B$      |

* The most recent earnings report (2024-08-02) showed a significant decline in EPS, missing analyst estimates. 
* Revenue growth has been consistent, but the negative EPS signals potential challenges for the company. 
* The company's future outlook will depend on its ability to address the factors contributing to the earnings decline.

**5. Summary:**

VRTX has a strong track record of outperformance compared to the S&P 500. Recent price movement indicates short-term upward momentum. However, technical indicators suggest potential overbought conditions and short-term downward pressure. The recent earnings report showed a significant decline in EPS, raising concerns about the company's future outlook. Investors should carefully analyze the factors behind the earnings decline and the company's plans to address them before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.